PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2122346
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2122346
According to Mordor Intelligence, the neuroendoscopy market size is expected to grow from USD 3.45 billion in 2025 to USD 3.63 billion in 2026 and is forecast to reach USD 4.7 billion by 2031 at 5.30% CAGR over 2026-2031.

This report is Segmented by Product Type (Rigid Neuroendoscopes and Flexible Neuroendoscopes), Usability (Reusable Neuroendoscopes and Single-Use Neuroendoscopes), Application (Transnasal Neuroendoscopy, and More), End User (Hospitals, and More), Patient Demographics (Adult and Pediatric) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).
The global prevalence of nervous-system disorders affects 3.8 billion people, and central-nervous-system tumors impose growing morbidity. Glioblastoma multiforme remains difficult to manage, spurring surgeons to adopt approaches that reduce cortical disruption while achieving maximal safe resection. Clinical studies published in 2024 show neuroendoscopic resections require craniotomy areas up to 70% smaller than conventional microsurgery, with comparably high extirpation rates and lower complication incidence. These outcomes reinforce the shift toward minimally invasive techniques as caseloads climb.
Real-time 3D reconstruction paired with neuroendoscopy has improved shunt placement accuracy for hydrocephalus, cutting malposition complications in recent multicenter trials. Purpose-built robotic arms stabilize instrumentation in narrow corridors and provide sub-millimetric tremor filtration, extending reach to previously inaccessible lesions. Together, these advances lift surgeon confidence and are shortening operating times in early adopter sites.
Procurement of neuronavigation-ready towers, high-resolution cameras and rigid scopes often exceeds a department's annual equipment budget in low-income settings. Ongoing calibration and service contracts further strain finances, widening the gap between high-income and middle-income facilities where neurosurgical needs are surging.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Rigid scopes captured 67.20% of 2025 revenue, underpinning the neuroendoscopy market share advantage of systems offering crystal-clear optics suited to intraventricular and skull-base corridors. Flexible scopes are accelerating at an 8.06% CAGR from 2026 to 2031. Manufacturers are shrinking distal tip diameters below 4 mm and integrating chip-on-the-tip cameras that rival reusable counterparts in resolution. Augmented-reality overlays now project anatomic landmarks directly onto surgeon displays, a capability under evaluation in multicenter trials.
Advances in polymer optics and recyclable packaging aim to mitigate environmental concerns cited by hospital sustainability boards. Early lifecycle assessments suggest carbon-neutral production of selected single-use models is achievable if renewable-energy inputs exceed 60% of total manufacturing consumption. As pricing narrows between premium reusable kits and turnkey disposable sets, hospitals are recalibrating value analyses that consider downtime due to scope damage or decontamination backlog.
Reusable units comprise 66.25% of the 2025 neuroendoscopy market size thanks to amortization over hundreds of procedures. Decontamination protocols, however, require multistep workflows that raise labor and chemical costs while exposing facilities to compliance lapses. NICE has cautioned that single-use scopes can be cost-ineffective when high-throughput reprocessing infrastructure exists, yet it also acknowledges reprocessing failures as a litigatory flashpoint.
Industrial design changes-detachable light cables, scratch-resistant sapphire windows and reinforced angulation mechanisms-are extending reusable scope lifespans beyond 2,000 cycles, bending cost curves in favor of retention. Parallel work on biodegradable polymers for single-use channels signals an eventual convergence where clinical, economic and environmental metrics can be met simultaneously.
North America led with 37.40% revenue in 2025, supported by advanced hospital networks, rapid FDA clearance pathways and high neurosurgical training density. AI-augmented planning platforms are increasingly integrated with navigation systems, sharpening resection margins and bolstering first-pass success rates.
Asia-Pacific is the fastest-growing region at 8.83% CAGR to 2031. Japan's aging population, coupled with universal coverage, drives robust equipment refresh cycles. China's domestic producers, such as Scivita Medical Technology, are challenging foreign incumbents, signaling a shift in vendor mix. India's public-private hospital expansion is widening access to endoscopic suites, while training exchanges with global centers raise procedural competency levels.
Europe maintains meaningful share as national health systems encourage minimally invasive strategies to trim lengths of stay. The Middle East and Africa are witnessing targeted investments in tertiary centers within the Gulf Cooperation Council and South Africa. In Latin America, Brazil and Argentina lead adoption, underpinned by academic partnerships and charitable outreach; the Neurosurgery Outreach Foundation has demonstrated scalable impact through 1,985 surgeries conducted across low-resource settings.